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Stress echocardiography (stress echo) is a method in which various stimuli are used to elicit 
myocardial contractility or provoke cardiac ischemia with simultaneous echocardiographic 
image acquisition of left ventricular function and valvular flow, if needed. The technique is a 
well-recognized, safe and widely available stress test used for the diagnosis and assessment 
of prognosis in coronary heart disease, but may also prove valuable in valvular heart disease. 
The stressors used include physical exercise, pharmacological agents (dobutamine, vasodila-
tors) and pacing stress, most often with the use of a permanent pacemaker. Two operators 
should perform the test: a physician experienced in stress echocardiography (at least 100 tests 
completed under supervision of an expert) and a trained nurse or another doctor. The labora-
tory should feature a defibrillator and a resuscitation kit with a set of pharmaceuticals, an 
intubation kit and an AMBU bag. Pacing stress echo requires an external programmer for the 
implanted permanent pacemaker. Exercise should be the preferred stressor for the diagnosis 
of ischemic heart disease with alternative of high-dose dobutamine test in cases of contraindi-
cations to physical stress. Pacing stress echo is recommended for patients with pacemakers, 
and dipyridamole test for the assessment of coronary flow reserve. Chest pain in patients with 
intermediate probability of coronary artery disease, inability to perform physical exercise and 
non-diagnostic resting or exercise electrocardiography are indications for stress echo. The test 
is also used in symptomatic patients after revascularization or patients qualified for revascu-
larization for functional assessment of coronary artery stenosis. Low-dose dobutamine test 
is usually performed in patients after myocardial infarction or with moderate-to-severe left 
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Introduction
Stress echocardiography (stress echo, SE) is a method in 
which various stimuli are used to elicit myocardial con-
tractility or provoke cardiac ischemia with simultaneous 
echocardiographic recording of left ventricular function 
and valvular flow, if needed(1–7). SE is used for the diagnosis 
of coronary heart disease and valvular heart defects. The 
stressors used include physical exercise, pharmacological 
agents (dobutamine, vasodilators) and pacing stress, most 
often with the use of a permanent pacemaker.
Methods 
Qualifications of medical personnel performing stress 
echo and laboratory equipment
The test should be performed by two operators: a physician 
experienced in stress echocardiography (at least 100 tests per-
formed under supervision of an expert) and a trained nurse or 
another doctor. The laboratory should feature a defibrillator 
and a resuscitation kit with a set of pharmaceuticals, an intu-
bation kit and an AMBU bag. Pacing stress echo requires an 
external programmer for the implanted permanent pacemaker.
Stress echo protocols
Exercise tests
Stress test may be performed on a treadmill or a cycle 
ergometer in a sitting or semi-recumbent position on the left 
side. Bruce protocol is used for treadmill: step increments by 
25 W every 3 minutes until termination criteria are reached 
(85% of max heart rate, contractility disorders, severe angi-
nal pain, ST elevation in ECG, and maximum stress load).
Pharmacological stress echo
Dobutamine tests
Dobutamine is a synthetic catecholamine increasing left ventric-
ular contractility, reducing ventricular afterload and, at higher 
doses, increasing heart rate. Dobutamine is administered in 
intravenous infusion, with doses increased every 3 minutes to 
5, 10, 20, 30, 40 µg/kg/min. If no clear increase in heart rate is 
observed, atropine is administered with a starting dose of 30 µg/
kg/min, at a maximum of 4 doses 0.25 mg each at 1-minute inter-
vals until target submaximal heart rate is reached. Intravenous 
metopropol at a dose of 2.5–5 mg should be used in the event of 
major myocardial ischemia with side effects. 
Vasodilator tests
Adenosine is an endogenous purine nucleoside. Under nor-
mal conditions, stimulation of adenosine receptors causes a 
4–5-fold increase in the coronary flow. In the case of coro-
nary stenosis, a steal phenomenon is observed.
Dipyridamole inhibits metabolism and increases the levels 
of endogenous adenosine, which results in the effects simi-
lar to those after intravenous adenosine. Patients should 
refrain from caffeine 12 hours and theophylline derivatives 
for 24 hours before the test.
Dipyridamole stress test involves an intravenous adminis-
tration of a total dose of 0.84 mg/kg within 6 minutes (or 
divided doses – 0.56 mg/kg within 3 minutes, followed by 
0.28 mg/kg for the next 3 minutes after a 4-minute inter-
val). Regardless of test results, intravenous aminophylline 
at 240 mg should be administered after test completion to 
reverse the effects of dipyridamole. In the adenosine test, 
the drug should be administered in an intravenous infusion 
at a maximum dose of 140 µg/kg/min for 6 minutes. 
Tests using vasodilators additionally allow for the measure-
ment of coronary reserve in the anterior descending left 
coronary artery. 
Pacing stress echo
Stress-pacing echocardiography can be performed in 
patients with a permanently implanted pacemaker. The 
pacemaker is externally programmed at 100-110 impulses/
min and then increased by 10 impulses/min every 3 minutes 
until 85% of maximum age predicted heart rate is reached, 
or a target rate of 150 impulses/min or maximum rate for 
a given pacemaker is reached. A rapid stress-testing pro-
tocol includes two stages: 3 minutes of stimulation at 100 
impulses/min and 3 to 5 minutes of 85% of maximum age 
predicted heart rate. In the case of grade II or III AV block, 
particularly during atrial stimulation, atropine (a total dose 
of 2 mg) may be used until 1:1 conduction is reached. The 
accuracy of the test in the assessment of coronary heart 
disease is very high, comparable to other stress echo tests. 
This is a non-invasive, safe and well-tolerated test that may 
be discontinued at any time. This technique should be con-
sidered in every patient with a pacemaker.
The use of contrast agents during stress echo
Contrast agents used in stress echocardiography are 
suspensions of encapsulated, gas-filled microbubbles. 
Following intravenous administration they pass through 
the pulmonary circulation and cause strong opacification 
of left cardiac chambers. They are administered intrave-
nously either as boluses or as constant rate continuous 
infusions with the ultrasound imaging set in harmonic 
mode. As their use improves visualization of endocar-
dial border, a suboptimal ultrasound window resulting in 
poor quality of images is the primary indication for the 
use of contrast agent. Attempts are also made to use con-
trast agents for the assessment of myocardial perfusion 
at rest and during stress (in Poland only for the purposes 
of research). Although contrast agents are safe, there are 
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3 – akinesia, 4 – dyskinesia), which allows calculation of 
the left ventricular contractility index at each stage (wall 
motion score index, WMSI – total score for segments visu-
alized/number of segments visualized). Reduced contractil-
ity in at least two segments is considered a positive result, 
indicative of ischemia. This does not apply to dyskinesia of 
a segment that is akinetic at rest as this segment may be 
passively ‘pushed out’ as a result of hyperkinesia of other 
ventricular elements. Contractility assessment should 
include centripetal movement and, most of all, systolic 
thickening of segments. A large number of segments with 
poor contractility, contractility disorders in areas supplied 
by more than one coronary artery (multivessel disease), 
significant deterioration of contractility (e.g. transition 
from normokinesia to akinesia or dyskinesia), short time 
between test onset and ischemia, long-lasting regression 
of contractility disorders at rest, and left ventricular dila-
tion during exercise are indicative of very severe ischemia. 
Absence of provoked contractility disorders using the full 
protocol indicates a negative result. The absence of new 
contractility disorders in the event of premature test dis-
continuation due to serious arrhythmia, excess increase in 
blood pressure above 220/120 mm Hg, a decrease in blood 
pressure below 90 mm Hg (or by 30 mm Hg below base-
line) and patient’s request are considered a non-diagnostic 
result.
Assessment of myocardial viability
Patients with significant ischemic left ventricular systolic 
dysfunction and reversible contractility disorders (involving 
at least four left ventricular segments) present with lower 
perioperative mortality, higher improvement of regional 
and general contractile function after invasive treatment, 
a lower number of heart failure symptoms and lower mor-
tality compared to patients with irreversible contractility 
disorders. An intravenous infusion of low-dose dobutamine 
(usually 5 and 10 µg/kg/min, 20 µg/kg/min, or 2.5, 5, 7.5, 
15, 20 µg/kg/min) administered at 3-minute (or 5-minute) 
stages, is used for the assessment of myocardial viability. 
Improved contractility of a given segment during dobuta-
mine infusion indicates its viability. Continuation of dobu-
tamine infusion in accordance with the protocol at doses of 
up to 40 µg/kg/min is recommended. A two-phase response 
including initial contractility improvement (at low dobu-
tamine doses), followed by impairment (at higher doses) 
is specific for preserved viability of myocardial segment 
supplied by a stenotic coronary artery and is considered to 
be the most precise prognostic indicator of improved left 
ventricular contractility after revascularization.
The role of stress echo in the diagnosis  
of coronary artery disease 
Stress echo is recommended for the diagnosis of ischemic 
heart disease: high-dose dobutamine test in the case of con-
traindications, pacing stress echo in patients with pace-
maker, and dipyridamole test for the assessment of coro-
nary flow reserve. Chest pain in patients with intermediate 
some limitations in clinically instable patients (including 
acute coronary syndrome). 
Three-dimensional echocardiography
Matrix-array transducers used in three-dimensional echo-
cardiography enable real-time recording of spatial data for 
the entire left ventricle. Simultaneous recording of several 
projections significantly reduces data acquisition time both 
at rest and during stress.
Quantitative analysis of regional systolic 
function
Quantitative analysis of regional myocardial function may 
be performed using tissue Doppler or acoustic marker 
tracking techniques. Muscle movement speed and strain, 
as well as strain rate are analyzed. Although quantitative 
analysis allows for objective assessment of regional myo-
cardial contractile function, it has not been included in 
stress echocardiography standards so far. 
The use of stress echo in coronary heart 
disease
Stress echo is performed for diagnostic purposes and/or 
prognosis estimation.
Diagnosis of myocardial ischemia
Unfeasibility or non-diagnostic result of stress ECG (failure 
to reach target heart rate during the test, left bundle branch 
block, stimulatory rhythm, resting repolarization abnor-
malities, skeletal diseases, lower limb atherosclerosis) is 
the most common indication for stress echocardiography. 
Stress and pharmacological tests show similar diagnostic 
sensitivity, specificity and accuracy in ischemia. The choice 
of stressor depends on limitations and contraindications, 
as well as preferences and experience in a given facility. 
According to guidelines, stress echocardiography has pri-
ority over stress electrocardiography, and exercise stress 
test is the first-choice option in patients able to exercise. 
Pharmacological or pacing stress test is performed in other 
patients. Coronary drugs (including beta-blockers) should 
be discontinued before the test unless contraindicated. 
Image acquisition in at least three basic projections, i.e. 
parasternal in the long and short axis, apical four-cham-
ber, two-chamber, and long axis, is performed at each stage 
with simultaneous recording of heart rate and arterial 
blood pressure. Doppler parameters are recorded as part 
of simultaneous valvular assessment. Recording standard-
ized cardiac cross-sections that are identical throughout 
the entire test is important for comparative analysis.
Segmental contractility analysis is based on left ventricular 
division into 17 or 16 segments. Each segment is scored 
between 1 and 4 (1 – normokinesia, 2 – hypokinesia, 
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probability of coronary artery disease, inability to perform 
physical exercise and non-diagnostic resting or exercise 
electrocardiography are indications for stress echo. The 
test is also used in symptomatic patients after revascu-
larization or patients qualified for revascularization for 
functional assessment of coronary artery stenosis. Low-
dose dobutamine test is usually performed in patients after 
myocardial infarction or with moderate-to-severe left ven-
tricular dysfunction to assess myocardial viability before 
potential revascularization.
Possible complications of stress echo
Death, cardiac arrest due to ventricular fibrillation or asys-
tole, myocardial infarction, shock, and pulmonary edema 
are the most severe, yet very rare complications of stress 
echo. Ventricular and supreventricular tachyarrhythmia, 
especially during dobutamine stress echo, are slightly more 
common. Anxiety, tremor, dyspnea, headache, palpitations, 
nausea, flushing, paresthesia, excess blood pressure eleva-
tion or drop may be experienced during dobutamine stress 
echo. Excess reduction of blood pressure or atrioventric-
ular block may occur during dipyridamole or adenosine 
stress echo. Pacing stress echo is the best-tolerated test. 
Pacing stress echo and stress echo are the safest tests. 
Contraindications to stress echo
Contraindications to stress echo include, among other con-
ditions, unstable coronary heart disease, decompensated 
heart failure, uncontrolled high blood pressure, severe ven-
tricular arrhythmias, endocarditis, myocarditis and peri-
carditis, as well as lack of patient’s consent.
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